Buprenorphine in the treatment of opioid dependence

British Journal of Hospital Medicine

Volumn 68, Issue 11, 2007, Pages 594-597

  George, Sanju ^a   Day, Ed ^b  

^a BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN ELIZABETH PSYCHIATRIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; NALTREXONE; PLACEBO;

CONTROLLED STUDY; DETOXIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; LOW DRUG DOSE; OPIATE ADDICTION; REVIEW; TREATMENT FAILURE;

EID: 36649000019     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2007.68.11.27681     Document Type: Review

References (24)

1. Ahmadi J (2002) A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran. Drug Alcohol Depend 66: 111-14
2. Auriacombe M (2001) Deaths attributable to methadone vs. buprenorphine in France. JAMA 285: 45
3. Berson A, Gervais A, Cazals D et al (2001) Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 34: 346-50
4. Connock M, Juarez-Garcia A, Jowett S et al (2007) Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment 11(9)
5. Dunlop AJ, Panjari M, O'Sullivan H, Henschke P, Love V, Ritter A, Lintzeris N (2003) Clinical Guidelines for the use of Buprenorphine in Pregnancy. Turning Point Alcohol and Drug Centre, Fitzroy
6. Eissenberg T, Johnson RE, Bigelow GE, Walsh SL, Liebson IA, Strain EC, Stitzer ML (1997) Controlled opiate withdrawal evaluation during 72 hour dose omission in buprenorphine maintained patients. Drug Alcohol Depend 45: 81-91
7. Gowing L, Ali R, White J (2006) Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, Issue 3. John Wiley and Sons, Ltd
8. Johnson RE, Strain EC, Amass L (2003) Buprenorphine: how to use it right. Drug Alcohol Depend 70: S59-S77
9. Kintz P (2002) Buprenorphine-related deaths. In: Kintz P, Marquet P, eds. Buprenorphine Therapy of Opiate Addiction. Humana Press, Totowa, NJ: 109-18
10. Law FD, Myles JS, Daglish MRC, Nutt DJ (2004) The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatrica 16: 246-74
11. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Kintaudi P (1998) Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93: 475-86
12. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L (2002) A randomized controlled trial of buprenorphine in the management of short term ambulatory heroin withdrawal. Addiction 97: 1395-404
13. Lintzeris N, Clark N, Muhleisen P, Ritter A (2006) National Clinical Guidelines and Procedures for the use of Buprenorphine in the Treatment of Heroin Dependence. Commonwealth of Australia, Canberra
14. Luty J, O'Gara C, Sessay M (2005) Is methadone too dangerous for opiate addiction? BMJ 331: 1352-3
15. Mendelson J, Jones RT (2003) Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend 70(1): S29-S37
16. National Treatment Agency for Substance Misuse (2005) Statistical Release: Statistics for Drug Treatment Activity in England 2004/5 from the National Drug Treatment Monitoring System. National Treatment Agency, London
17. National Treatment Agency for Substance Misuse (2007) The NTA's 2006 National Prescribing Audit. National Treatment Agency, London
18. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP (2001) Injecting misuse of buprenorphine among French drug users. Addiction 96: 267-72
19. Oppenheimer E, Toubutt C, Taylor C, Andrew T (1994) Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow up study. Addiction 89: 1299-308
20. Perez de los Cobos J, Martin S, Etcheberrigaray A et al (2000) A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend 59: 223-33
21. Royal College of General Practitioners (2004) Guidance for the use of buprenorphine for the treatment of opioid dependence in primary care. Royal College of General Practitioners, London (www.smmgp.co.uk/html/guidance.php accessed 15 August 2007)
22. Sigmon SC, Moody DE, Nuwayser ES, Bigelow GE (2006) An injection depot formulation of buprenorphine: extended biodelivery and effects. Addiction 101: 420-32
23. Stoller KB, Bigelow GE, Walsh SL, Strain EC (2001) Effects of buprenorphine/naloxone in opioid dependent humans. Psychopharmacohgy 154: 230-42
24. Walter DS, Inturrisi CE (1995) Absorption, distribution, metabolism, and excretion of buprenorphine in animals and humans. In: Cowan A, Lewis JW, eds. Buprenorphine: Combating Drug Abuse with a Unique Opiate. Wiley-Liss, New York: 113-35